Pharma Mar S.A. Logo

Pharma Mar S.A.

Biopharmaceutical company developing oncology treatments from marine sources.

PHM | MC

Overview

Corporate Details

ISIN(s):
ES0169501022 (+1 more)
LEI:
959800QWKZ45ZQC2AV58
Country:
Spain
Address:
Avenida de los Reyes 1 Polígono Industrial La Mina, 28770 Colmenar Viejo

Description

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-10-28 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-10-24 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-10-08 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-09-22 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-19 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-18 00:00
Se informa que todas las propuestas de acuerdos presentadas por el Consejo a la…
Spanish 389.6 KB
2025-06-18 00:00
Se remite copia de la presentación a accionistas que será realizada en la Junta…
Spanish 2.5 MB
2025-06-09 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-09 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-05 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-26 17:41
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
Spanish 171.3 KB
2025-05-23 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-22 00:00
Motivo de la notificación: Persona Estrechamente Vinculada
Spanish 91.4 KB
2025-05-21 08:27
La Sociedad presenta la solicitud en la UE para comercializar lurbinectedina en…
Spanish 744.9 KB

Automate Your Workflow. Get a real-time feed of all Pharma Mar S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharma Mar S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharma Mar S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.